# Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants

> **NCT03236844** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 114 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Gantenerumab

## Key facts

- **NCT ID:** NCT03236844
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2017-12-15
- **Final completion:** 2017-12-15
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2018-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03236844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03236844, "Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03236844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*